MIRM Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -10.38%, SMA50 0.84%, SMA200 32.39%). The stock’s 14-day RSI is 38.75 (weak momentum), while the ATR of 4.57 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -15.64% below its high and over 149.97% above its low. Average 10-day trading volume of 464.36 thousand shares is below the 3-month average of 769.28 thousand, indicating normal recent market interest.

Mirum Pharmaceuticals, Inc. has 50.24 million shares outstanding. The public float is 39.99 million shares, elevated short interest at 13.25% of float. This equals 6.63 million shares. The short ratio is 17.23 days. Institutional investors hold 116.16% of the float. Insiders own 1.39%. SANDELL SCOTT D holds 4.19 million shares, Chang Carmen has 4.19 million shares and New Enterprise Associates 16, L.P. has 4.19 million shares. Over the past six months, insider transactions show net selling. They sold 169.04 thousand shares across 21 transactions.

Mirum Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.79. This means the shares are trading above this model’s fair value.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) closed at $100.54 USD, gaining $2.24 (2.28%) from the previous close of $98.30. The stock is currently mid-range between its 52-week high and low $63.23 and $130.00. With a market capitalization of about $6.13 billion, Mirum Pharmaceuticals, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.49). Key stats such as the average daily volume over the past year has been around 777.35 thousand shares, volume is running light vs its 52-week average. Headquartered in Foster City, CA, Mirum Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Christopher Peetz, the company employs approximately 433 people and listed since July 18, 2019. Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions.

Mirum Pharmaceuticals, Inc. generated EPS of -$0.86 over the past year. Five-year average earnings growth is 4.14%. The latest quarter delivered EPS of -$0.80. The next quarter is forecast at -$0.21. Next year's EPS is expected at $93.32. Analyst sentiment is bullish. Analyst rating data shows there are 25 Strong Buy ratings, 14 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $175.00 to $77.00. The high target offers 78.03% upside. The low target suggests -21.67% downside. The mean target is $122.79. This offers 24.91% upside. Mirum Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended August 05, 2026, missed forecasts by 7.74%. The prior quarter beat by 3576.73%. Over the last six quarters, Apple has recorded several small beats. These include -23.08% in May 07, 2025.

Our AI price prediction model suggests that Mirum Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.6%, with price expected at $98.89 by September 23, 2026, within a range of $95.82 to $102.09 3-Month Outlook: Projected fall of -32.73%, reaching $66.13 by December 08, 2026, with a range of $64.87 to $67.51. 1-Year Outlook: Projected gain of 30.93%, with price at $128.70 by September 09, 2027, within a range of $124.41 to $132.77.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) shares are up 16.33% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Mirum Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -6.81. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $83.96, suggesting -14.59% downside. Our AI forecast model points to short-term strength (0.6% over two weeks), a medium-term fall (-32.73% over three months), and a longer-term gain (30.93% over one year), with expected trading ranges indicating moderate volatility.

Mirum Pharmaceuticals, Inc. trades at a P/E ratio of -6.81, slightly below the S&P 500 average, with a price-to-sales ratio of 9.79 and a price-to-book ratio of -603.16 indicating negative book value, which may reflect financial stress. The P/FCF stands at -13.2, also below market averages.